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Open access under the Ela b s t r a c t
The pharmacological inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] has
been largely employed as a c-JUN N-terminal kinase (JNK1/2) inhibitor. In this study, we evaluated
whether pretreatment with SP600125 was able to prevent Orthopoxviruses Vaccinia virus (VACV), Cow-
pox virus (CPXV) and modiﬁed Vaccinia virus Ankara (MVA) replication. We found that incubation with
SP600125 not only blocked virus-stimulated JNK phosphorylation, but also, signiﬁcantly reduced virus
production. We observed 1–3 log decline in viral yield depending on the cell line infected (A31, BSC-
40 or BHK-21). The reduction in viral yield correlated with a dramatic impact on virus morphogenesis
progress, intracellular mature viruses (IMV) were barely detected. Despite the fact that SP600125 can
act as an efﬁcient anti-orthopoxviral compound, we also provide evidence that this antiviral effect is
not speciﬁcally exerted through JNK1/2 inhibition. This conclusion is supported by the fact that viral
titers measured after infections of JNK1/2 knockout cells were not altered as compared to those of
wild-type cells. In contrast, a decline in viral titers was veriﬁed when the infection of KO cells was carried
out in the presence of the pharmacological inhibitor. SP600125 has been the focus of recent studies that
have evaluated its action on diverse viral infections including DNA viruses. Our data support the notion
that SP600125 can be regarded as a potential antipoxviral compound.
 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
The Orthopoxviruses encompass a family of large, double-
stranded DNA viruses, approximately 200 kbp in size, whose repli-
cation is entirely carried out in the cytoplasm of infected cells
(Condit et al., 2006; Moss, 2007). In 1980, the World Health Orga-
nization (WHO) declared that smallpox (Variola) – a devastatingução de Sinal/Orthopoxvirus-
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sevier OA license. human disease caused by Variola virus (VARV) – was eradicated
(Fenner et al., 1988; Barquet and Domingo, 1997; Smith and McF-
adden, 2002). With its eradication, vaccination was discontinued.
As a consequence, much of the world’s population has either never
been immunized or has not been immunized for more than
30 years. Either scenario results in a population that is extremely
susceptible to variola or other poxviruses.
Our laboratory is interested in dissecting poxvirus-host cell
interactions. We have observed that pharmacological inhibition
of the MEK/ERK pathway with UO126 or PD98059 decreased virus
yield by at least one order of magnitude (de Magalhães et al., 2001;
Andrade et al., 2004). Moreover, pretreatment of cells with
LY294002, a pharmacological inhibitor of the PI3K/Akt pathway,
decreased Vaccinia virus (VACV) or Cowpox virus (CPXV) replica-
tion by 99% (Soares et al., 2009). Here we show that SP600125,
an anthrapyrazolone inhibitor of the c-JUN N-terminal kinases 1/
2 (JNK1/2) (Bennett et al., 2001), caused a signiﬁcant decrease in
viral yield of VACV, CPXV and modiﬁed Vaccinia virus Ankara
(MVA). Although SP600125 is regarded as a speciﬁc JNK inhibitor
(Bennett et al. 2001), our ﬁndings demonstrate that its antipoxviral
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other than JNK1/2. Since SP600125 has proved to be efﬁcient
in vitro against diverse viral infections such as inﬂuenza (Mehrotra
et al., 2007), rotavirus (Holloway et al., 2006) and herpesvirus (Za-
pata et al., 2007; Hamza et al., 2004; Perkins et al., 2003; Chen
et al., 2002), we propose a potential use of this compound to treat
poxviruses infection or complications associated with vaccination.
2. Materials and methods
2.1. Cell culture, antibodies and chemicals
A31 cells (a clone derived from mouse Balb/c 3T3), BSC-40,
BHK-21 and mouse embryonic ﬁbroblasts (MEFs) from WT and
double knockout (KO) JNK1/2/ cells (Tournier et al., 2000), were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with heat-inactivated fetal bovine serum (FBS), (% v/v),
as follows: BSC-40 (6%); BHK-21 (10%) and JNK (5%), and antibiot-
ics in 5% CO2 at 37 C. FBS was purchased from Cultilab, Campinas,
SP, Brazil. A31 cells were kindly provided by Sogayar (Department
of Biochemistry, University of São Paulo, Brazil). Davis (Howard
Hughes Medical Institute, University of Massachusetts Medical
School, Worcester, MA) gently provided us with WT and JNK1/2
KO cells. The following rabbit polyclonal antibodies were pur-
chased from Sigma–Aldrich (São Paulo, Brazil): anti b-Tubulin or
Cell Signaling Technology (Beverly, MA): anti-phospho JNK1/2
(Thr183/Tyr185), anti-c-JUN (Ser73), anti-total ERK1/2, as were
the horse radish peroxidase (HRP) conjugated anti-rabbit and
anti-mouse secondary antibodies. Both SP600125 [anthra(1,9-
cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] (structural formula
below) and the JNK Inhibitor VIII (JNKi VIII) - (N-(4-amino-5-cya-
no-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenylacetamide),
were purchased from Calbiochem (São Paulo, Brazil); inhibitors
were diluted in DMSO to a ﬁnal concentration of 25 mM
(SP600125) and 4 mM (JNKi VIII) and stored at 20 C.2.2. Viruses
(A) Viral stocks: Wild-type VACV (strain WR) and CPXV (strain
BR) were propagated in Vero or BSC-40 cells. MVA was propagated
in BHK-21 cells. Viruses were then highly puriﬁed by sucrose gra-
dient sedimentation as described (Joklik, 1962). The experiments
presented in this study were carried out using the intracellular ma-
ture virus (IMV) form of the virus. (B) Viral infection: Cells were al-
lowed to reach 80–90% conﬂuence and starved by changing the
media to 1% FBS for 12 h. Cells were infected at the indicated mul-
tiplicity of infection (MOI) for the times shown. When needed, cells
were treated with the indicated compound for 30 min prior to viral
infection and incubated in the continued presence of the drug.
2.3. Multi-step viral growth curves
Thirty ﬁve millimeter dishes of A31, BSC-40, BHK-21 and JNK1/
2 KO cells (density 5  105 cells/dish) were starved and infected at
an MOI of 10 for the indicated times 3, 6, 12, 24, 36 and 48 h eitherin the absence or in the presence of SP600125 (40 lM) or JNKi VIII
(4 lM). At each time point, cultures were washed with cold PBS,
and cells were disrupted by freeze/thawing. Supernatant were col-
lected and the viral yield was quantiﬁed by viral plaque assay as
described (da Silva et. al., 2006). Data were conﬁrmed by at least
three independent experiments with similar results.
2.4. Electron microscopy
BSC-40 cells were infected with VACV (MOI of 2) either in the
absence or in the presence of SP600125 (40 lM) and incubated
at 37 C for 18 h. Cells were ﬁxed with 2.5% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4) for 1 h at room temperature,
scraped gently, and collected by centrifugation. The cells were
washed with cacodylate buffer, postﬁxed with 1% osmium tetrox-
ide, dehydrated in acetone and processed for conventional trans-
mission electron microscopy. Thin sections were examined with
a Morgagni transmission electron microscope operating at 80 kV.
2.5. Cytotoxicity assays
Conﬂuent 35 mm dishes of A31 or BSC-40 cells were treated
with increasing concentrations (10, 20, 40 and 50 lM) of
SP600125. At 48 h, an equal volume of Trypan Blue stain was
added to each well. Cells were stained for 10 min at room temper-
ature after which time the stain was removed and cells were ob-
served for any evidence of stain absorption (an indication of
cellular membrane permeability and death). We found that
P90% of the cells pretreated with SP600125 at 40 lM were not
stained. This concentration was used throughout the experiments.
A dose response including 0.4, 4 and 40 lM of JNKi VIII was also
performed for cytotoxicity assays and 4 lM was employed in our
experiments.
2.6. Western blotting
(A) Lysate preparation – A31 and BSC-40 cells were starved and
infected with VACV or CPXV (MOI = 10) in the presence or absence
of SP600125. At the indicated times, cells were washed with cold
PBS and disrupted on ice with lysis buffer [100 mM Tris–HCl (pH
8,0), 1% Triton X-100, 0.2 mM EDTA, 20% glycerol (v/v), 200 mM
NaCl, 1 mM NaVO3 (sodium orthovanadate), 1 mM PMSF (phen-
ylmethanesulfonyl ﬂuoride), 5 lg/mL aprotinin, 2.5 lg/mL leupep-
tin, 1 mM DTT]. Whole cell lysates were collected by centrifugation
at 13,500 rpm for 15 min at 4 C. Protein concentration was deter-
mined by the Bio-Rad assay. (B) Electrophoresis and immunoblotting
– Forty microgram of protein per sample were separated by elec-
trophoresis on a 10% SDS polyacrylamide gel and transferred to
nitrocellulose membranes (de Magalhães et al., 2001). Brieﬂy,
membranes were blocked at room temperature for 1 h with PBS
containing 0.1% Tween-20 and 5% (w/v) non-fat milk. The mem-
branes were washed three times with PBS containing 0.1%
Tween-20, incubated with speciﬁc polyclonal or monoclonal anti-
body (1:1000–1:3000) in PBS containing 0.1% Tween-20 and 5%
(w/v) BSA, followed by incubation with the HRP-conjugated sec-
ondary anti-rabbit Ab (1:3000) or anti-mouse Ab (1:1000). Immu-
noreactive bands were visualized by the ECL detection system as
described in the Manufacturer’s instructions (GE Healthcare, UK).3. Results
3.1. VACV and CPXV infection stimulate JNK1/2 phosphorylation
In order to investigate whether the cellular stress associated
with orthopoxvirus infection led to the activation of the
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(JNKs), BSC-40 cells were infected with VACV or CPXV. At 3, 6,
12, 24 and 36 h post-infection (h.p.i) whole cell lysates were col-
lected and subjected to western blot to evaluate the phosphoryla-
tion status of JNK1/2. Our data (Fig. 1A and B) demonstrated that
both CPXV and VACV infections were able to stimulate JNK1/2
phosphorylation (JNK1/2-P) as early as 3 h.p.i., and to a maximal
level reached at late times in the infective cycle, 36 h.p.i. As a con-
trol, and as expected, we observed no difference in the levels of
ERK1/2 during infection. Additionally, viral stimulation of JNK1/
2-P was blocked in a dose-dependent manner [10, 20, 40 and
50 lM (Fig. 1C, lanes 4–7)] when VACV infection was performed
in the continued presence of SP600125. Similar results were ob-
tained with CPXV infection (data not shown).
3.2. SP600125 inhibits VACV, CPXV and MVA growth
In order to investigate whether the Orthopoxvirus-stimulated
JNK1/2-P was biological relevant to the virus, we performed mul-
ti-step viral growth curves (MOI = 10) in the presence or absence
of SP600125. Cellular extracts were collected at 3, 6, 12, 24, 36
and 48 h.p.i and assayed for viral yield. We observed that the
SP600125-mediated inhibition played a relevant role in both VACV
and CPXV biology. A signiﬁcant reduction in the viral titers (P1 log
reduction) was observed when VACV (Fig. 2A) or CPXV (Fig. 2B)
infections were carried out in the continued presence of
SP600125. To verify that the inhibitory effect associated with
SP600125 was not restricted to the A31 cells, BSC-40 were infected
with VACV or CPXV as described above. As shown in Fig. 2C and D,
treatment with SP600125 resulted in a severe decrease in viral pro-
duction (2–3 log reduction) thereby demonstrating that viralFig. 1. VACV and CPXV infection stimulate JNK1/2 phosphorylation. BSC-40 cells were
shown. (C) Cells were left uninfected (MOCK) or infected (VACV) and treated with SP600
(40 lg) were prepared, subjected to western blot and probed with anti-phospho JNK1/2 (
as a loading control – lower panels. Data are representative of three distinct experimengrowth inhibition is not cell-type speciﬁc. Additionally, we investi-
gated whether SP600125 was able to affect MVA replication. To
that end, BHK-21 cells were infected with MVA as described above.
Again, our results showed (Fig 2E) that the inhibitor caused a sig-
niﬁcant decline in virus yield (nearly 3 log reduction); while a
more mild decrease (1 log) in infectivity was noted with VACV
and CPXV (2F and 2G). The variation in the levels of inhibition
caused by SP600125 might be due to the viruses’ tropism within
different species such as murine (A31 cells), monkey (BSC-40 cells)
and hamster (BHK-21 cells).3.3. SP600125 severely compromise progress of Orthopoxviruses
morphogenesis
In order to investigate at what stage the progression of the viral
cycle was affected by SP600125, BSC-40 cells were left untreated
(Fig 3A, B and C) or were pretreated with the inhibitor (Fig 3D, E,
F and G) and infected with VACV at an MOI of 2. At 18 h.p.i, in-
fected cells were harvested and examined by electron microscopy.
While infected cells in the absence of inhibitor (panels A, B and C)
contained the full spectrum of virion morphogenesis forms charac-
terized by the identiﬁcation of crescent, spherical, immature viri-
ons (IV), immature virions with nucleoids (IVN) and brick-shaped
mature virions (IMV), cells pre-incubated with SP600125 (panels
D, E, F and G) showed a severe impairment of morphogenesis pro-
gression. Large virosomes surrounded by crescents were repeat-
edly detected. IVs could be also observed, however IVNs or IMVs
were rarely seen. Identical phenotype was also observed when
cells were infected with CPXV in the presence of SP600125 (data
not shown).left uninfected (MOCK) or were infected with CPXV (A) or VACV (B) for the times
125 (10, 20, 40 or 50 lM) prior to and during viral infection (lanes 4–7). Cell lysates
Thr183/Tyr185) – upper panels, or probed with anti-ERK1/2 or anti-b actin antibody
ts with similar results.
Fig. 2. SP600125 inhibits VACV, CPXV and MVA growth. Multi-step growth curves - A31 cells (A, B), BSC-40 (C, D) and BHK-21(E–G) were CPXV- (A, C, G), VACV- (B, D, F) and
MVA- (E) infected at an MOI of 10, for the indicated times, either in the absence or presence of SP600125 (40 lM). Cell lysates were collected and viral yields were
quantitated. Data are representative of three distinct experiments with similar results.
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of JNK1/2
Although SP600125 has been characterized as a speciﬁc JNK
pharmacological inhibitor (Bennett et al., 2001), a growing body
of evidence suggests that SP600125 may be an inhibitor of other
kinases as well (Bain et al., 2003, 2007; Bogoyevitch and Arthur,
2008). Thus, to further deﬁne whether the reduction in viral yields
associated with SP600125 treatment was a direct consequence of
JNK1/2 inhibition, WT (Fig. 4A) or JNK1/2 KO MEF cells (Fig. 4B)were infected with VACV or with CPXV. Infections were carried
out either in the absence or presence of SP600125 (40 lM) or the
pharmacological inhibitor of JNK (JNKi VIII - 4 lM). After 24 h, in-
fected cells were collected and assayed for viral production. As
shown in Fig. 4A and B, in the absence of any inhibitor, the viral ti-
ters were comparable when produced in either cell line (WT or JNK
KO cells lines). This observation strongly suggests that neither
VACV nor CPXV require JNK for productive infection. Furthermore,
both the WT and JNK KO cells were equally susceptible to
SP600125, while being refractory to JNKi VIII treatment.
Fig. 3. SP600125 blocks virion maturation during orthopoxvirus morphogenesis. Electron microscopy analysis – A31 cells were either left untreated (A–C) or treated with
SP600125 prior to VACV (D–G) infection at MOI of 2 for 18 h. Cells were then ﬁxed and prepared for transmission electron microscopy. Electron micrographs are shown with
their scale indicated by the bars. Abbreviations: ⁄ – Crescents, IV – immature virus, IVN – immature virions with nucleoids, IMV – intracellular mature virus, N – nucleus, M –
mitochondria, V - virosome. Panel G is a close up image of panel F. Data is representative of two independent experiments with similar results.
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lication, we evaluated the phosphorylation levels of its substrate,
c-Jun, during viral infection in the presence or absence of either
SP600125 or JNKi VIII. Both compounds are known as reversible
ATP-competitive JNK inhibitors that ultimately block phosphoryla-
tion of JNK substrates such as c-Jun (Bennet et al., 2001; Vivanco
et al., 2007). Fig. 4C shows that both SP600125 and JNKi VIII af-
fected VACV- and CPXV-stimulated c-Jun phosphorylation (c-Jun-
P). Taken together these ﬁndings demonstrated that even though
both pharmacological inhibitors targeted the same downstream
substrate of JNK (c-Jun), viral replication was only affected in the
presence of SP600125. Thus, our data strongly suggest that
SP600125 is targeting kinase(s) other than JNK1/2 and, therefore,
provide evidence of its JNK-independent inhibitory action.4. Discussion
Smallpox was announced eradicated by WHO in 1980 and since
then, vaccination has been discontinued. As a consequence, much
of the world’s population is vulnerable and, therefore, under con-tinuous threat. Moreover, even though the smallpox vaccine
(VACV) was successfully used in the WHO’s eradication program,
the vaccine has an imperfect safety record and cannot be used with
those having immunological deﬁciency or eczema (Fenner et al.,
1988; Barquet and Domingo, 1997; Smith and McFadden, 2002).
Furthermore, the re-emergence of CPXV in Europe (Vorou et al.,
2008), Monkeypox virus (MPXV) outbreaks in Africa and the Uni-
ted States (Sejvar et al., 2004; Reynolds et al., 2004; Formenty
et al., 2010), and the emergence of VACV in Brazil (Fonseca et al.,
1998; Damaso et al., 2000; Trindade et al., 2007), emphasizes the
need for searching for new antipoxviral compounds with potential
use in clinical trials.
Currently, the only antiviral agent currently approved by FDA
(Food and Drug Administration) for use against Orthopoxviruses
is cidofovir (CDV), an acyclic nucleoside phosphonate analogue,
which is known to inhibit not only poxvirus replication but also
the replication of a variety of other DNA viruses such as herpesvi-
rus, adenovirus, papillomavirus, and polyomavirus (De Clercq,
2003). In 2009, it was shown that cidofovir impairs Vaccinia DNA
encapsidation and, consequently, affects viral morphogenesis (Je-
sus et al., 2009). In humans, cidofovir has been used successfully
Fig. 4. Inhibition of VACV and CPXV growth by SP600125 is independent of JNK1/2. WT (A) and JNK1/2 KO (B) cells were either left untreated or treated with SP600125
(40 lM), or with JNK Inhibitor VIII (4 lM) prior to VACV or CPXV infection at an MOI of 10. At 24 h.p.i, total cell lysates were assayed for viral production. (C) Cells were left
uninfected (MOCK) or were treated with SP600125 or JNKi at (4 lM) (lanes 5, 6 and 8, 9), as indicated. Total cell lysates (40 lg) were prepared, subjected to western blot and
probed with anti-phospho c-JUN (Ser 73) – upper panels, or probed with anti-b tubulin antibody (1:3000) as a loading control – lower panels. Data are representative of three
distinct experiments with similar results.
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nal toxicity is a known side effect caused by this drug (De Clercq,
2002). Importantly, cidofovir-resistant strains of camelpox, cow-
pox, monkeypox and vaccinia viruses have also been isolated
(Smee et al., 2002). To overcome nephrotoxicity, a derivative form
of CDV has been generated and tested. CMX001 is a lipid conjugate
of the acyclic nucleotide phosphonate and is currently in Phase II
clinical trials for the prophylaxis of human cytomegalovirus infec-
tion and under development using the Animal Rule for smallpox
infection. CMX001 has demonstrated in vitro and in vivo efﬁcacy
against orthopoxvirus infections, and no evidence of nephrotoxi-
city in either animals or humans was found. Both drugs target
the viral DNA polymerase, and VACV strains have been shown to
be cross resistant to CMX001 as well.
A new class of anti-poxvirus drugs, which affects both viral
spread and dissemination, has also emerged. One of them, ST-
246, has been intensely tested against a number of Orthopoxvirus
species in animal studies (Yang et al., 2005a,b; Sbrana et al., 2007;
Quenelle et al., 2007). ST-246 speciﬁcally inhibits the viral protein
F13, which is required for the formation of enveloped virus forms.
Similar to CDV in which viral resistance is conferred by point
mutations in the DNA polymerase gene (Becker et al., 2008), it
has also been described that a single point mutation in F13 con-
ferred resistance to ST-246 (Yang et al., 2005a,b). ST-246 was re-
cently tested in a Phase I clinical trial and found to be well
tolerated and safe in healthy humans (Jordan et al., 2008, 2010).An additional approach to inhibit viral multiplication is target-
ing cellular signaling pathways stimulated and required for suc-
cessful replication and dissemination. In the past years, we and
others have shown the ability of the Orthopoxviruses VACV and
CPXV to induce protein kinases pathways to provide an adequate
environment to favor their viral replication cycles (de Magalhães
et al., 2001; Andrade et al., 2004; da Silva et al., 2006; Mercer
and Helenius, 2008; Soares et al., 2009; McNulty et al., 2010). It
is also known that poxviruses use the Src and Abl family kinase
activities to modulate intracellular spread and release (Frischkn-
echt et al., 1999; Reeves et al., 2005, 2011) but only the Abl family
of kinases mediate release of CEV to form EEV (Reeves et al., 2005).
Therefore, tyrosine kinase inhibitors originally developed for treat-
ing cancers have also been tested against many poxviruses. One of
these drugs is imatinib mesylate (STI-571; Gleevec), which is ap-
proved for treating human cancers (Tolomeo et al., 2009; Wolf
and Rumpold, 2009). Gleevec speciﬁcally inhibits the Abl family
of kinases, reducing VACV dissemination in vivo (Reeves et al.,
2005). It has been suggested that cardiotoxicity can be a side-effect
caused by this drug; but even targeting cellular kinases may bring
attention about unwanted side effects (Kerkelä et al., 2006), it
seems that drug resistance cannot readily develop, which is a ben-
eﬁt for antiviral chemotherapy.
The anthrapyrazolone inhibitor of c-JUN N-terminal kinases 1/2
(JNK1/2), SP600125 (Bennett et al., 2001; Bogoyevitch et al., 2004),
the focus of this manuscript, has been largely utilized as a potential
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inﬂammation and neurodegeneration (Sharma et al., 2010; Holm
et al., 2011; Hu and Liu, 2009; de Borst et al., 2009; Wang et al.,
2009; Song et al., 2008). Some derivatives of SP600125 are being
tested in diverse clinical trials (Manning and Davis, 2003; Bogoyev-
itch et al., 2004; Bennett, 2006; Bogoyevitch and Arthur, 2008). In
addition, the antiviral effects of SP600125 have been investigated
in diverse viral models suggesting that JNK inhibitors may provide
new therapeutic interventions (Manning and Davis, 2003; Bogo-
yevitch and Arthur, 2008). For instance, it has been shown that
the viral kinase ORF36 of the Kaposi’s sarcoma-associated herpes-
virus activates JNK1/2 and its inhibition by SP600125 blocks viral
gene expression at late stages of infection (Hamza et al., 2004).
Varicella-zoster virus (VZV) replication was also decreased in a
dose-dependent manner by treatment with SP600125 (Zapata
et al., 2007). Another report showed that SP600125 inhibited the
activation of JNK by the hepatitis C virus protein NS3, which con-
tributes to hepatitis C related hepatocarcinogenesis (Hassan
et al., 2005). Furthermore, the use of signal transduction pathways
modulators, either singly (Yang et al., 2005a,b; Reeves et al., 2005)
or in combination, could be the most appropriate therapeutic strat-
egy. In fact, it has been shown that SP600125 used together with
inhibitors of phosphatidylinositol 3-kinase/Akt prevented the
establishment of persistent SARS-CoV infection (Mizutani et al.,
2005).
While studying the Orthopoxviruses VACV, CPXV, and MVA-
cell host- interaction, we found that SP600125 exerted an antivi-
ral effect. Our results showed a dramatic reduction in virus yield
when infections were performed in the presence of this inhibi-
tor. Electron microscope images demonstrated that in the pres-
ence of SP600125, Orthopoxviruses replication is compromised;
normal-looking IVs are frequently seen but IVN are very rare
and no IMVs could be detected (Fig 3, Bottom panel).
SP600125 is considered as a speciﬁc pharmacological inhibitor
of JNK1/2, not only in response to cytokine stimulation (Dong
et al., 2000), but also with viral infections (Bogoyevitch and
Arthur, 2008). Our results show that upon VACV or CPXV infec-
tion JNK1/2 is activated during the entire viral cycle and
SP600125, indeed, inhibits JNK1/2 phosphorylation in a dose-
dependent manner (Fig 1C). However, the block identiﬁed in
the viral cycle caused by SP600125 is an event that occurs inde-
pendently of JNK1/2 since no effect on viral yield was observed
when infections were performed in JNK1/2 KO MEF cells. Similar
results were found with the use of JNKi VIII inhibitor.
Previous reports have shown that SP600125 inhibits cellular ki-
nases in vitro other than JNK1/2 (Bain et al., 2003, 2007), but even
in the face of the concerns raised on the speciﬁcity of this inhibitor,
several studies still rely on this drug for a possible therapeutic
application regarding treatment of human diseases. Furthermore,
since its discovery in 2001, SP600125 has been extensively studied
for treatment of numerous non-viral diseases in murine model
(Ikezumi et al., 2004; Gao et al., 2005; Han et al., 2005; Gunawan
et al., 2006; Guan et al., 2006; Takamura et al., 2007; Syrkina
et al., 2007; Hu and Liu, 2009). However, up to the publication of
this work, a search in the literature did not show a single report
demonstrating that SP600125 is effective against viral infection
in animal studies to support the results observed in cell culture
system. Furthermore, studies have shown that viral infection can
lead to JNK activation and the inhibition of these cellular kinases
by SP600125 affects viral multiplication (Hamza et al., 2004; Has-
san et al., 2005; Zapata et al., 2007; Gupta et al., 2011).
Most of these studies make a strict connection between the
inhibition of JNK by SP600125 and its impact on viral infection.
Because JNK is only one of the kinases targeted by this drug, addi-
tional analyses with other inhibitors of JNK1/2 or cell lines knock-
outs for those kinases or even RNAi approach should be takeninto consideration to conﬁrm this direct relationship. Therefore,
since animal studies are a cost, time and energy-dependent sys-
tem, it is possible that researchers are more careful about taking
a step further and testing SP600125 in mice, for instance, and do
not succeed in correlating the data observed in tissue culture.
Additional disadvantages of SP600125 may be considerable off-
target activity, or perhaps its poor solubility in aqueous solution
or/and possible undesirable side-effects (Bennett et al., 2001; Bain
et al., 2003; Begleiter et al., 2006). In effort to get around these
complications, a derivative of SP600125 (CC-401) was developed
by Celgene has successfully completed a Phase I trial in healthy
volunteers as stated by the pharmaceutical company. CC-401
has also been reported in Phase II evaluation for the treatment
of acute myelogenous leukemia, and has also been considered
for the treatment of respiratory diseases (Roberts and Der,
2007; Bogoyevitch and Arthur, 2008). Nevertheless, a shortest
path to evaluate SP600125 in vivo against an orthopoxvirus infec-
tion would be a viral challenge in a murine model.
Taken together, questions still remain regarding the potential
protein kinase(s) targeted by SP600125 during Orthopoxvirus
infection causing the impairment of viral morphogenesis. Poxvi-
ruses encode two essential serine/threonine kinases, B1 (Trakt-
man et al., 1989; Lin et al., 1992; Rempel and Traktman, 1992)
and F10 (Lin and Broyles, 1994). While B1 plays a function dur-
ing viral DNA replication (Traktman et al., 1989; Rempel et al.,
1990; Domi and Beaud, 2000), F10 plays a role in the very early
stages of virion morphogenesis (Wang and Shuman, 1995; Trakt-
man et al., 1995). When B1 or F10 proteins are repressed or
inactive, none of the hallmarks of morphogenesis are identiﬁed.
Therefore, it is doubtful that SP600125 would target one or both
viral kinases. In addition, some viral proteins that play a role in
morphogenesis are proposed to be also phosphorylated by cellu-
lar kinases (Resch et al., 2005; Unger and Traktman, 2004; Wick-
ramasekera and Traktman, 2010). By comparison with electron
microscopy images of VACV mutants, under nonpermissive con-
ditions, we observed that some of them phenotypically copy our
results when infections are performed in the presence of
SP600125. The repression of the phosphoprotein A13L arrests
morphogenesis at the stage of IV formation. Essentially, no IMVs
are seen and IVNs are rare; DNA crystalloids accumulate in the
cytoplasm (Unger and Traktman, 2004). A similar phenotype is
also seen when H3L, a major immunodominant protein, is re-
pressed or deleted (da Fonseca et al., 2000). When the myristoy-
lated L1R protein is repressed, the transition from IV to IMV is
blocked (Ravanello et al., 1994). Thus far, it is hard to predict
a putative cellular target for SP600125 that would affect viral
morphogenesis. Steps that prior and subsequently lead to the
formation and maturation of IMVs are very complex and not
fully understood. Protein phosphorylation, protein–protein inter-
actions and proteolytic processing are some of the events in-
volved. Since cellular kinases are likely thought to contribute
to phosphorylation of viral proteins, it is plausible that their
inhibition by SP600125 could affect those events blocking mor-
phogenesis progress.
In conclusion, our results demonstrate the use of SP600125
inhibits Orthopoxviruses replication in a JNK independent-manner.
This suggests that other cellular and/or viral substrates are affected
by the action of SP600125. While signiﬁcant progress has been
made in the discovery of novel compounds against Orthopoxvirus-
es, the need for a range of antiviral drugs is imperative since the
occurrence of resistance to antiviral drugs is not a rare event.
Our data support the notion that SP600125 can be regarded as a
potential antipoxviral compound; the combined use of SP600125
with other antipoxviral drugs may enhance their antiviral activity
and, perhaps, minimize major side effects with the advantage of
reducing drug resistance.
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